Ann: Annual Report to shareholders 2014, page-2

Some points:

David King

Diagnostics "In addition, the Company has entered into new research collaborations during the past year, and we aim to translate these efforts into further licensing opportunities in the future."

Hair Products:  "In Japan, a distribution agreement was signed in late 2013 allowing for new product launch in October 2014. We have signed our first distribution agreement in China and business development efforts in other major markets including the USA, Europe and South America are well advanced."

Clinical Trial  "A safe outcome in this study would add significant value not only to CAB102, but also to Cellmid’s other therapeutic programs."

Maria Halasz

Animal Studies: "However, three of the six MK antibody candidates significantly reduced tumour growth when combined with carboplatin. CAB102 has shown the greatest efficacy reducing mean tumour volumes at 21 days post treatment by 50%."

My take :  (Not 5% ,not 15%, not disease free progression of 3 months  ..... 50% tumour mass reduction in just 21 days IS news.  If repeated in late stage human patients the SP will ..........  )

Clinical Trial "MK antibody program is primed to enter the clinic in 2015"

Tribodies "As our lead antibody CAB102 is entering clinical development, and a potential pipeline of products is on the horizon. Cellmid’s MK antibody program is entering a truly exciting and company changing period."

CXBladder "In their 2014 Annual Report Pacific Edge Chairman, Chris Swann, reiterated their earlier projections of $100 million sales after five full years of trading. Cellmid will receive single digit royalties on net sales."

Quest: "Their estimate for the target market of the test is 7 million people annually, who are at high risk for lung cancer."  [in the US that is]

Advangen  "Whilst not formally acknowledged on the Company’s balance sheets, it is likely that the value of Cellmid’s import permits to China have increased significantly since acquisition."

cheers